论文部分内容阅读
目的观察脑卒中后抑郁症患者采用小剂量米氮平联合疏肝解郁胶囊治疗的临床效果。方法选择该院2012年10月-2014年10月收治的脑卒中后抑郁症患者100例,给予小剂量米氮平联合疏肝解郁胶囊治疗。观察患者的临床疗效及不良反应发生情况,治疗前后比较患者的抑郁程度、认知功能及神经功能缺损情况,患者的抑郁程度采用汉密尔顿抑郁量表(HAMD)评定,认知功能采用简易精神状态检查量表(MMSE)评定,神经功能缺损采用临床神经功能缺损量表(CSS)评定。结果 100例患者中治愈52例(52%),有效42例(42%),无效6例(6%),总有效率为94%。治疗后患者的HAMD评分及CSS评分均低于治疗前,MMSE评分高于治疗前,差异均有统计学意义(P<0.05)。结论小剂量米氮平联合疏肝解郁胶囊用于脑卒中后抑郁症抗抑郁效果较好,可显著改善患者的认知功能和神经功能,具有临床推广价值。
Objective To observe the clinical effect of low dose mirtazapine combined with Shugan Jieyu capsule in patients with post-stroke depression. Methods A total of 100 patients with post-stroke depression who were admitted from October 2012 to October 2014 in our hospital were treated with low dose mirtazapine and Shugan Jieyu capsules. The clinical efficacy and adverse reactions of the patients were observed. The degree of depression, cognitive function and neurological deficit were compared between before and after treatment. The degree of depression was evaluated by Hamilton Depression Rating Scale (HAMD). The cognitive function was assessed by mental state examination Scale assessment (MMSE), neurological deficit using clinical neurological deficit scale (CSS) assessment. Results Of the 100 patients, 52 (52%) were cured, 42 (42%) were effective, 6 (6%) were ineffective and the total effective rate was 94%. The HAMD score and CSS score of patients after treatment were lower than before treatment, MMSE score was higher than before treatment, the difference was statistically significant (P <0.05). Conclusion Low dose mirtazapine combined with Shugan Jieyu Capsule is effective in depressing depression after stroke. It can significantly improve the cognitive function and neurological function of patients, and has clinical value of popularization.